Navigating Advances in Neovascular Retinal Disease: Translating Evidence to Practice in AMD, DME, and RVO

Release Date: October 15, 2025

Expiration Date: October 15, 2026

Activity Overview

This online, on-demand virtual symposium brings together renowned experts in neovascular retinal diseases including AMD, DME and RVO. In this educational program, these experts use a case-based format to discuss the latest data regarding management of these disorders and share their perspectives and best practices.

This educational activity is an archive of the live virtual symposium held on August 1, 2025.

The activity is designed to highlight and test participants on the most recent and clinically relevant data in managing neovascular retinal disease with next generation anti-VEGF agents, provide expert guidance on the interpretation of core concepts, and forecast the clinical impact of recent data sets.

Target Audience

This activity is directed toward retina specialists, comprehensive ophthalmologists, optometrists, and other eye care professionals involved in the treatment of neovascular retinal disease.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Interpret clinical trial data and real-world evidence supporting the use of next generation anti-VEGF agents for RVO
• Identify patients suitable for extended-interval dosing for nAMD based on baseline characteristics, early fluid response, and real-world insights from recent data.
• Incorporate evidence-based strategies for optimizing extended dosing intervals in the management of DME, minimizing treatment burden, and improving long-term visual outcomes in clinical practice.